Today: 5 February 2026
Subscribe
Browse Category

NASDAQ:TARA News 5 December 2025

Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025

Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025

Published: December 5, 2025 Protara Therapeutics, Inc. (NASDAQ: TARA) is ending the week in dramatic fashion. After a string of positive clinical updates for its lead cell therapy TARA‑002, the company has tapped equity markets with a $75 million public offering that has sent the stock down roughly 20% today, even as Wall Street price targets still imply several‑fold upside…
5 December 2025
·····

Stock Market Today

  • Crown Holdings Surpasses Q4 2025 Revenue Expectations with 7.7% Growth
    February 4, 2026, 6:15 PM EST. Crown Holdings (NYSE:CCK), a metal packaging products manufacturer, reported Q4 CY2025 revenue of $3.13 billion, beating analyst estimates by 3.6% and marking a 7.7% year-on-year increase. Adjusted earnings per share (EPS) came in at $1.74, 2.2% above expectations. Adjusted EBITDA reached $501 million, a 1.4% beat with a 16% margin. CEO Timothy J. Donahue highlighted record adjusted EBITDA of $2.1 billion for 2025, up 8% from 2024. Despite strong quarterly results, the company's long-term sales growth remains modest, with a five-year compound annual growth rate (CAGR) of 1.3%. Analysts project 2.1% revenue growth for 2026, suggesting limited catalysts for enhanced top-line performance.
Go toTop